Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.

IMPORTANCE Knowledge of the immunogenicity of biologic agents may be helpful for the development of strategies for treatment of chronic immune-mediated inflammatory diseases. OBJECTIVE To summarize the influence of antibodies against biologic agents (AABs [seropositivity]) on efficacy and safety in immune-mediated inflammatory diseases. DATA SOURCES MEDLINE, EMBASE, Cochrane Library, and the Web of Knowledge were searched for articles published in English, Spanish, French, Italian, or Portuguese between 2000 and March 2012. The search strategy focused on synonyms of diseases, immunogenicity, and biologic agents. Abstracts from 2001 to 2011 of the European League Against Rheumatism and American College of Rheumatology congresses were also included. STUDY SELECTION The selection criteria were (1) observational or interventional studies in rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, spondyloarthritis, and psoriasis; (2) studies including patients who received biologic agents; and (3) studies collecting data on AABs. DATA EXTRACTION AND SYNTHESIS Data collected included publication details, study design, characteristics of patients and treatments, presence of antibodies, and definition of response. MAIN OUTCOMES AND MEASURES The primary end point was the association of AABs with response to treatment. Secondary end points were the association of AABs with safety, the association of AABs with concentration of the drug, and the influence of use of concomitant immunosuppressive therapy in the formation of AABs. RESULTS The search captured 10 728 articles and abstracts. By hand and reverse search, 31 articles were additionally included. After evaluation of the full reports, 60 references were selected. They included 59 studies of anti-tumor necrosis factor monoclonal antibodies: 1 with etanercept, 2 with rituximab, and 2 with abatacept. In rheumatoid arthritis but not in inflammatory bowel disease or spondyloarthritis, seropositive patients presented worse clinical response at 6 months or less (odds ratio [OR], 0.03; 95% CI, 0.01-0.21), and at 6 months or more (0.03; 0.00-0.30) by meta-analysis. In rheumatoid arthritis, discontinuation of the biologic agent for all reasons was more common in seropositive patients (OR, 3.53; 95% CI, 1.60-7.82). In all conditions, seropositive patients had a higher risk of hypersensitivity reactions (OR, 3.97; 95% CI, 2.36-6.67). Overall, concomitant treatment with disease-modifying antirheumatic drugs, including azathioprine, decreased the risk of seropositivity (OR, 0.32; 95% CI, 0.25-0.42). CONCLUSIONS AND RELEVANCE Presence of antibodies against anti-tumor necrosis factor monoclonal antibodies confers a risk of discontinuation of treatment in rheumatoid arthritis and a risk of development of hypersensitivity reactions in all immune-mediated inflammatory diseases. The combined use of anti-tumor necrosis factor monoclonal antibodies and disease-modifying antirheumatic drugs reduces the development of antibodies and subsequent risks. Information on other biologic agents is fragmentary.

[1]  P. V. van Riel,et al.  The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.

[2]  P. Peloso,et al.  The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[3]  S. Berney.  Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis , 2009 .

[4]  K. Bendtzen,et al.  Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease , 2011, Scandinavian journal of gastroenterology.

[5]  R. Farrell,et al.  Immunogenicity of Biological Agents in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[6]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[7]  C. Wouters,et al.  2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension , 2008, Pediatric Rheumatology Online Journal.

[8]  Matthias Schneider,et al.  Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. , 2011, Rheumatology.

[9]  John C. Davis,et al.  Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. , 2008, Arthritis and rheumatism.

[10]  J. Gómez-Reino.  Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. , 2012, Rheumatology.

[11]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[12]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[13]  L. Aarden,et al.  Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. , 2008, Current opinion in immunology.

[14]  H. Nakagawa,et al.  Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study , 2010, The Journal of dermatology.

[15]  P. Rutgeerts,et al.  Cytokine blockade in inflammatory bowel diseases. , 2011, Immunotherapy.

[16]  Hervé Watier,et al.  Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases , 2011, Arthritis research & therapy.

[17]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[18]  F. Armbruster,et al.  Immunogenicity, efficacy and adverse events of adalimumab in RA patients , 2006, Rheumatology International.

[19]  G. Wolbink,et al.  Therapy: Immunogenicity of biologic therapies—we need tolerance , 2010, Nature Reviews Rheumatology.

[20]  L. Aarden,et al.  Dealing with immunogenicity of biologicals: assessment and clinical relevance , 2009, Current opinion in rheumatology.

[21]  W. Sandborn.  Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. , 2003, Gastroenterology.

[22]  C. Aybay,et al.  Anti‐infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study , 2010, The Journal of dermatology.

[23]  E. Bonfá,et al.  Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases , 2010, Clinical reviews in allergy & immunology.

[24]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[25]  L. Aarden,et al.  Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[26]  B. Dijkmans,et al.  High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment , 2006, Annals of the rheumatic diseases.

[27]  A. Moss,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.

[28]  B J Biggerstaff,et al.  Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis. , 1997, Statistics in medicine.

[29]  G Van Assche,et al.  Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment , 2011, Gut.

[30]  S. Travis,et al.  Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review , 2009, Inflammatory bowel diseases.

[31]  B. Dijkmans,et al.  Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. , 2009, Arthritis and rheumatism.

[32]  E. D. De Jong,et al.  Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. , 2010, Archives of dermatology.

[33]  J. Kremer,et al.  Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. , 2010, Arthritis and rheumatism.

[34]  P. Sarzi-Puttini,et al.  Autoantibody production in patients treated with anti-TNF-α , 2008, Expert review of clinical immunology.

[35]  E. Martı́n-Mola,et al.  Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. , 2011, Rheumatology.

[36]  B. Dijkmans,et al.  The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept , 2010, Annals of the rheumatic diseases.

[37]  C. Aybay,et al.  Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis , 2006, Rheumatology International.

[38]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[39]  P. V. van Riel,et al.  Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study , 2011, BMC musculoskeletal disorders.

[40]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[41]  P. Limburg,et al.  The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. , 2010, Clinical and experimental rheumatology.

[42]  B. Dijkmans,et al.  Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation , 2006, Annals of the rheumatic diseases.

[43]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[44]  W. Lems,et al.  The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review , 2010, Arthritis Research & Therapy.

[45]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[46]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[47]  K. Bendtzen,et al.  Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. , 2012, Journal of Crohn's & colitis.

[48]  M. Hartmann,et al.  Autoantibodies in psoriasis as predictors for loss of response and anti‐infliximab antibody induction , 2011, The British journal of dermatology.

[49]  G. Assche.  Immunogenicity of anti-TNF antibodies. Has the veil been lifted? , 2011 .

[50]  B. Dijkmans,et al.  Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation , 2009, Annals of the rheumatic diseases.

[51]  D. Scott.  Biologics‐Based Therapy for the Treatment of Rheumatoid Arthritis , 2012, Clinical pharmacology and therapeutics.

[52]  J. Ortonne,et al.  Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy , 2011, The British journal of dermatology.

[53]  Jill Hayden,et al.  Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.

[54]  E. Kuipers,et al.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.

[55]  D. Gladman,et al.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial , 2006, Annals of the rheumatic diseases.

[56]  F. Wolfe,et al.  Consensus recommendations for the assessment and treatment of rheumatoid arthritis. , 2001, The Journal of rheumatology.

[57]  A. Matucci,et al.  Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.

[58]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[59]  K. Bendtzen,et al.  Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies , 2009, Scandinavian journal of gastroenterology.

[60]  S. Agarwal,et al.  Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial , 2010, The Journal of Rheumatology.

[61]  R. Scrivo,et al.  Autoantibody production in anti-TNF-alpha-treated patients. , 2007, Annals of the New York Academy of Sciences.

[62]  B. Dijkmans,et al.  Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study , 2009, Annals of the rheumatic diseases.

[63]  B. Dijkmans,et al.  Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[64]  G. Stucki,et al.  The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice? , 2002, Rheumatology.

[65]  B. Dijkmans,et al.  Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[66]  Mahboob Rahman,et al.  Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab bef , 2009, Arthritis and rheumatism.

[67]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[68]  B. Dijkmans,et al.  Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. , 2008, Arthritis and rheumatism.

[69]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[70]  F. Breedveld,et al.  An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status , 2008, Clinical Rheumatology.

[71]  R. Dodge,et al.  Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. , 2007, The Journal of rheumatology.

[72]  P. Anderson.  Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. , 2005, Seminars in arthritis and rheumatism.

[73]  U. Kopylov,et al.  The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful , 2010, Gut.

[74]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[75]  H. Hashimoto,et al.  A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.

[76]  K. Bendtzen,et al.  Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.

[77]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[78]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[79]  L. Chatenoud,et al.  Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. , 2006, Clinical immunology.

[80]  C. Wouters,et al.  A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[81]  W. Sandborn,et al.  Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials , 2009, Alimentary pharmacology & therapeutics.

[82]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[83]  C. Gabay,et al.  Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. , 2010, Joint, bone, spine : revue du rhumatisme.

[84]  Mahboob Rahman,et al.  Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study , 2008, Annals of the rheumatic diseases.

[85]  A. John,et al.  Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. , 2008, Bulletin of the NYU hospital for joint diseases.

[86]  B. Dijkmans,et al.  Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study , 2010, Arthritis research & therapy.

[87]  P. Tak,et al.  Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[88]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[89]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[90]  P. Lipsky,et al.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.

[91]  A. Bouaziz,et al.  Golimumab and immunogenicity? 2010 and beyond. , 2011, Die Pharmazie.

[92]  K. Bendtzen,et al.  Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[93]  D. Cella,et al.  Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[94]  P. Rutgeerts,et al.  Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[95]  K. Bendtzen,et al.  Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease , 2008, The American Journal of Gastroenterology.

[96]  L. Aarden,et al.  Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. , 2012, Journal of immunological methods.

[97]  K. Das,et al.  Non‐response to infliximab may be due to innate neutralizing anti‐tumour necrosis factor‐α antibodies , 2008, Clinical and experimental immunology.

[98]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[99]  M. P. Schön,et al.  Predicting the unpredictable: autoantibody profile as parameter to foretell individual responses to infliximab treatment? , 2011, The British journal of dermatology.

[100]  K. Dickersin,et al.  Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. , 1992, JAMA.

[101]  M. Malaise,et al.  DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment , 2005, Arthritis research & therapy.

[102]  J. Pelletier,et al.  Immunogenicity of biologic agents: A new concern for the practicing rheumatologist? , 2007, Current rheumatology reports.

[103]  M. Kosmač,et al.  Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab , 2011, Pediatric Research.

[104]  J J Anderson,et al.  Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. , 2001, Arthritis and rheumatism.

[105]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[106]  J. Tcheng,et al.  Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. , 2003, Developments in biologicals.

[107]  S. Vermeire,et al.  Immunogenicity of infliximab: how to handle the problem? , 2007, Acta gastro-enterologica Belgica.

[108]  Viswanath Devanarayan,et al.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.

[109]  L. Aarden,et al.  Differential effect of drug interference in immunogenicity assays. , 2011, Journal of immunological methods.

[110]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[111]  K. Stubenrauch,et al.  Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. , 2010, Clinical therapeutics.

[112]  N. Miyasaka.  Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study , 2008, Modern rheumatology.

[113]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[114]  B. Haraoui,et al.  Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. , 2006, The Journal of rheumatology.

[115]  B. Dijkmans,et al.  Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation , 2007, Annals of the rheumatic diseases.

[116]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[117]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[118]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[119]  G. Lichtenstein.  Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial , 2008 .

[120]  T. Vergou,et al.  Autoimmunity by anti‐tumour necrosis  factor‐alpha agents: the role of traditional therapies , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[121]  B. Pariente,et al.  Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.

[122]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[123]  Mahboob Rahman,et al.  Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. , 2008, Arthritis and rheumatism.

[124]  A. Andoh,et al.  Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease , 2012, Journal of Gastroenterology.